Figure 1. Next-generation sequencing in NSCLC. (A) Percentages of non-silent somatic single nucleotide variants identified by next-generation sequencing (whole-genome/whole-exome/targeted sequencing) in 13 NSCLC patients. (B) Numbers and types of non-silent somatic mutations. (C) Mutations identified by next-generation sequencing in 13 NSCLC patients and in a validation group of 88 NSCLC patients. The type of each mutation is shown for every sample, and the number of subjects (n) with mutations is listed on the right. AC, lung adenocarcinoma. SCC, lung squamous cell carcinoma. ASCC, lung adenosquamous carcinoma.